Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2025)

Indivior Pharmaceuticals has reported Total Liabilities over the past 5 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $1.3 billion for Q4 2025, down 21.31% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 21.31% YoY), and the annual figure for FY2025 was $1.3 billion, down 21.31%.
  • Total Liabilities for Q4 2025 was $1.3 billion at Indivior Pharmaceuticals, down from $1.6 billion in the prior quarter.
  • Over the last five years, Total Liabilities for INDV hit a ceiling of $1.9 billion in Q4 2023 and a floor of $161.0 million in Q1 2024.
  • Median Total Liabilities over the past 5 years was $1.6 billion (2021), compared with a mean of $1.3 billion.
  • Peak annual rise in Total Liabilities hit 931.06% in 2025, while the deepest fall reached 21.31% in 2025.
  • Indivior Pharmaceuticals' Total Liabilities stood at $1.6 billion in 2021, then increased by 5.46% to $1.7 billion in 2022, then grew by 13.04% to $1.9 billion in 2023, then fell by 14.93% to $1.7 billion in 2024, then dropped by 21.31% to $1.3 billion in 2025.
  • The last three reported values for Total Liabilities were $1.3 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.